ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > STAT3

STAT3

概要

Name:Signal transducer and activator of transcription 3
Target Synonym:Acute-phase response factor,APRF,STAT3,Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor),Signal transducer and activator of transcription 3,DNA-Binding Protein APRF,ADMIO1,ADMIO,HIES,STAT3 Transcription Factor
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
ST3-H5149 Human Human STAT3 Protein, His Tag (MALS & SPR verified)
ST3-H5149-structure
ST3-H5149-sds
CHEK-ATF047 Human STAT3 (Luc) HEK293 Reporter Cell
ACRO Quality

生物活性データの一部

ST3-H5149-SPR
 STAT3 SPR

Human STAT3, His Tag (Cat. No. ST3-H5149) immobilized on CM5 Chip can bind STAT3 degrader with an affinity constant of 44.6 nM as determined in a SPR assay (Biacore 8K) (QC tested).

ST3-H5149-BLI
 STAT3 BLI

Loaded Human STAT3, His Tag (Cat. No. ST3-H5149) on NTA Biosensor, can bind STAT3 degrader with an affinity constant of 29.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

STAT3, signal transducer and activator of transcription 3

Background

Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes important for essential cellular processes including survival, proliferation, self-renewal, angiogenesis, and immune response. As an early tumor diagnostic marker, it is considered that constitutive STAT3 activation is a sufficient factor to cause malignant transformation and tumor development in model systems. The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Caffeic Acid CABE Approved The University Of Texas MD Anderson Cancer Center, Moleculin Llc Hemorrhage; Leukopenia; Thrombocytopenia Details
Golotimod SCV-07 Approved Verta Russian Federation Hepatitis C; Mucositis null 2009-01-01 Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
GLG-302 GLG-302; GLG-805; S31-201; NSC-74859 Phase 1 Clinical H Lee Moffitt Cancer Center & Research Institute Breast Neoplasms Details
M-1001 M-1001; MEDICA-M1001 Phase 2 Clinical Syndromex Dyslipidemias Details
Amcasertib/Napabucasin Phase 1 Clinical Boston Biomedical Inc Neoplasms Details
HL-237 HL-237 Phase 2 Clinical Hanlim Pharmaceutical Co Ltd Arthritis, Rheumatoid Details
Danvatirsen AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx Phase 2 Clinical Ionis Pharmaceuticals Inc Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CO-sTiRNA CO-sTiRNA Phase 1 Clinical City Of Hope National Medical Center Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
KT-333 KT-333; I-003 Phase 1 Clinical Kymera Therapeutics Inc Solid tumours; Lymphoma, T-Cell, Peripheral; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
WP-1066 WP-1066 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Medulloblastoma; Neoplasms; Glioblastoma; Brain Neoplasms; Brain metastases; Glioma; Melanoma Details
Napabucasin DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) Phase 3 Clinical 1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc Solid tumours; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
C-188-9 C188-9; C-188-9; TTI-101 Phase 2 Clinical Baylor College Of Medicine Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
NT-219 NT-219; NT219 Phase 2 Clinical TyrNovo Ltd Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis Details
Dimethylaminomicheliolide Fumarate ACT-001 Phase 2 Clinical Accendatech Co Ltd Ganglioglioma; Glioblastoma; Optic Neuritis; Central Nervous System Neoplasms; Neuromyelitis Optica; Breast Neoplasms; Glioma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
PCUR-101 PCUR-101 Phase 1 Clinical Pellficure Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details

This web search service is supported by Google Inc.

totopphone